인플루엔자 백신 시장 규모, 점유율 및 동향 분석 보고서 : 백신 유형별, 적응증별, 연령층별, 투여 경로별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

Influenza Vaccine Market Summary

The global influenza vaccine market size was estimated at USD 8,924.13 million in 2025 and is projected to reach USD 14,797.35 million by 2033, growing at a CAGR of 6.51% from 2026 to 2033. The influenza vaccine sales are expected to increase throughout the forecast period due to an increase in the incidence of seasonal flu and increased recommendations for vaccination against the disease.

According to the WHO, influenza cases have significantly increased as of early 2026, with the US experiencing a severe season, with estimates of over 15 million cases, 180,000 hospitalizations, and 7,400 deaths.According to the CDC's estimates published in October 2023, nearly one billion cases of seasonal influenza are reported globally, including around 3-5 million cases with complications. In addition, a surge in surveillance and government support for vaccination at the country and global levels to monitor vaccine distribution, supply, and administration is one of the growth drivers for the influenza vaccine industry.

The global influenza vaccine industry continues to demonstrate stable and essential growth in the post-pandemic period, supported by sustained awareness of respiratory infectious diseases and the normalization of annual immunization programs. While the surge witnessed during COVID-19 has moderated, vaccination uptake remains higher than pre-pandemic levels in several countries, driven by improved public health awareness and institutional preparedness. According to the CDC, the 2023-2024 influenza season resulted in an estimated 28-35 million illnesses, 310,000-390,000 hospitalizations, and 20,000-25,000 deaths in the U.S., highlighting the continued burden of disease and the critical role of vaccination.

Innovation remains a key growth driver in the influenza vaccine market, particularly with the advancement of next-generation and combination vaccines. Companies are increasingly investing in mRNA-based and recombinant technologies to enhance vaccine efficacy and reduce production timelines. For instance, in October 2023, Moderna, Inc. announced positive Phase 1/2 data for its mRNA-1083 combination vaccine targeting both COVID-19 and influenza, demonstrating a strong immune response against multiple strains. Additionally, Pfizer and BioNTech continued progressing their mRNA-based influenza and combination vaccine candidates into mid-stage clinical trials in 2024.

The market is supported by strong regulatory backing and expanding immunization guidelines globally. Organizations such as the World Health Organization (WHO) continue to update biannual recommendations on strain composition, ensuring vaccine effectiveness against circulating variants. In 2024, the WHO emphasized the inclusion of updated influenza A (H1N1 and H3N2) and influenza B strains in seasonal vaccines. Governments worldwide are also strengthening stockpiling strategies and public vaccination campaigns to mitigate seasonal outbreaks and potential co-infections with other respiratory viruses.

Global Influenza Vaccine Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global influenza vaccine market report based on vaccine type, indication, age group,route of administration, distribution channel, and region:

• Vaccine Type Outlook (USD Million, 2021 - 2033)
• Inactivated
• Live Attenuated
• Indication Outlook (USD Million; 2021 - 2033)
• Quadrivalent
• Trivalent
• Age Group Outlook (USD Million; 2021 - 2033)
• Pediatric
• Adults
• Route of Administration Outlook (USD Million; 2021 - 2033)
• Injection
• Nasal Spray
• Distribution Channel Outlook (USD Million; 2021 - 2033)
• Hospitals & pharmacy
• Government & Institutional Supply
• Other
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Influenza Vaccine Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Vaccine Type Segment
    • 1.1.1.2. Indication Segment
    • 1.1.1.3. Age Group Segment
    • 1.1.1.4. Route of Administration Segment
    • 1.1.1.5. Distribution Channel Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Influenza Vaccine Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Vaccine Type Snapshot
• 2.3. Indication Snapshot
• 2.4. Age Group Snapshot
• 2.5. Route of Administration Snapshot
• 2.6. Distribution Channel Snapshot
• 2.7. Competitive Landscape Snapshot

Chapter 3. Influenza Vaccine Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraint Analysis
• 3.4. Porter's Five Forces Analysis
• 3.5. PESTLE Analysis
• 3.6. Pipeline Analysis

Chapter 4. Influenza Vaccine Market: Vaccine Type Estimates & Trend Analysis

• 4.1. Global Influenza Vaccine Market: Vaccine Type Dashboard
• 4.2. Global Influenza Vaccine Market: Vaccine Type Movement Analysis
• 4.3. Global Influenza Vaccine Market by vaccine type, Revenue
• 4.4. Inactivated
  • 4.4.1. Inactivated market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Live Attenuated
  • 4.5.1. Live Attenuated market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Influenza Vaccine Market: Indication Estimates & Trend Analysis

• 5.1. Global Influenza Vaccine Market: Indication Dashboard
• 5.2. Global Influenza Vaccine Market: Indication Movement Analysis
• 5.3. Global Influenza Vaccine Market by Indication, Revenue
• 5.4. Quadrivalent
  • 5.4.1. Quadrivalent market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Trivalent
  • 5.5.1. Trivalent market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Influenza Vaccine Market: Age Group Estimates & Trend Analysis

• 6.1. Global Influenza Vaccine Market: Age Group Dashboard
• 6.2. Global Influenza Vaccine Market: Age Group Movement Analysis
• 6.3. Global Influenza Vaccine Market by Age Group, Revenue
• 6.4. Pediatric
  • 6.4.1. Pediatric market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Adults
  • 6.5.1. Adults market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Influenza Vaccine Market: Route of Administration Estimates & Trend Analysis

• 7.1. Global Influenza Vaccine Market: Route of Administration Dashboard
• 7.2. Global Influenza Vaccine Market: Route of Administration Movement Analysis
• 7.3. Global Influenza Vaccine Market by Route of Administration, Revenue
• 7.4. Injection
  • 7.4.1. Injection market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Nasal Spray
  • 7.5.1. Nasal Spray market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Influenza Vaccine Market: Distribution Channel Estimates & Trend Analysis

• 8.1. Global Influenza Vaccine Market: Distribution Channel Dashboard
• 8.2. Global Influenza Vaccine Market: Distribution Channel Movement Analysis
• 8.3. Global Influenza Vaccine Market by Distribution Channel, Revenue
• 8.4. Hospitals & pharmacy
  • 8.4.1. Hospitals & pharmacy market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Government & Institutional Supply
  • 8.5.1. Government & Institutional Supply market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Other
  • 8.6.1. Other market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Influenza Vaccine Market: Regional Estimates & Trend Analysis

• 9.1. Regional Dashboard
• 9.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 9.3. North America
  • 9.3.1. U.S.
    • 9.3.1.1. Key country dynamics
    • 9.3.1.2. Regulatory framework/ reimbursement structure
    • 9.3.1.3. Competitive scenario
    • 9.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3.2. Canada
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework/ reimbursement structure
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3.3. Mexico
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework/ reimbursement structure
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 9.4. Europe
  • 9.4.1. UK
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework/ reimbursement structure
    • 9.4.1.3. Competitive scenario
    • 9.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework/ reimbursement structure
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.3. France
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework/ reimbursement structure
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.4. Italy
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework/ reimbursement structure
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.5. Spain
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework/ reimbursement structure
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.6. Norway
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework/ reimbursement structure
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.7. Sweden
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework/ reimbursement structure
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Regulatory framework/ reimbursement structure
    • 9.4.8.3. Competitive scenario
    • 9.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.3. India
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/ reimbursement structure
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.4. Australia
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework/ reimbursement structure
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework/ reimbursement structure
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework/ reimbursement structure
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.2. Argentina
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 9.7. MEA
  • 9.7.1. South Africa
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.3. UAE
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.4. Kuwait
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
  • 10.3.3. Key company market share analysis, 2025
  • 10.3.4. GSK plc
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Product benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Pfizer Inc
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Product benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Sanofi
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Product benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. Vaxess Technologies Inc
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Product benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Merck & Co., Inc.
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Product benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Viatris Inc.
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Product benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. OSIVAX
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Product benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. AstraZeneca
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Product benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. SINOVAC
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Product benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. CSL Limited
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Product benchmarking
    • 10.3.13.4. Strategic initiatives
  • 10.3.14. EMERGENT
    • 10.3.14.1. Company overview
    • 10.3.14.2. Financial performance
    • 10.3.14.3. Product benchmarking
    • 10.3.14.4. Strategic initiatives
  • 10.3.15. EMERGEX VACCINES
    • 10.3.15.1. Company overview
    • 10.3.15.2. Financial performance
    • 10.3.15.3. Product benchmarking
    • 10.3.15.4. Strategic initiatives